ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on drug CONCORD, Mass., Oct. 22, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.